GBS Ib CRM-glycoconjugate vaccine + GBS III CRM-glycoconjugate vaccine

**GBS Ib CRM-glycoconjugate vaccine + GBS III CRM-glycoconjugate vaccine** is a bivalent vaccine candidate consisting of capsular polysaccharides from Group B Streptococcus (GBS) serotypes Ib and III conjugated to the CRM197 carrier protein (a detoxified diphtheria toxin variant). This conjugation enhances immunogenicity by converting T-cell independent polysaccharide antigens into T-cell dependent ones, eliciting robust IgG responses and immunological memory for protection against invasive GBS disease. It targets maternal immunization to prevent neonatal infections like early-onset disease (EOD) and late-onset disease (LOD), as well as stillbirths, with serotypes Ib and III being among the most prevalent globally. Developed as part of broader multivalent GBS vaccine efforts (e.g., trivalent Ia/Ib/III formulations by GSK), it uses linkers like HZ-PEG-HZ for optimal conjugation and has shown preclinical immunogenicity and safety in animal models, with functional opsonophagocytic activity.

Other names

GBS Ib-CRM197 conjugate + GBS III-CRM197 conjugate